Glepaglutide

Human clinical Healing & Recovery 3 sources

Glepaglutide is a long-acting glucagon-like peptide-2 (GLP-2) analog developed primarily for the treatment of short bowel syndrome (SBS). Research shows it promotes intestinal growth, increases fluid and nutrient absorption, and may reduce the need for parenteral support in patients with compromised intestinal function.

01Dosing reference

Amount

1 mg to 10 mg

Frequency

Once or twice weekly

Cycle

Continuous use as prescribed for chronic management of SBS

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

GLP-2 Receptor Activation

Binds to and activates the GLP-2 receptor located in the gastrointestinal tract.

Intestinal Trophic Effect

Stimulates the growth of intestinal mucosa, increasing villus height and crypt depth, which expands the absorptive surface area.

Enhanced Absorption

Improves the absorption of fluids, electrolytes, and nutrients, reducing the dependency on intravenous feeding (parenteral support).

03Human evidence

Phase 3 EASE trials demonstrated that glepaglutide significantly reduced the volume of parenteral support required by patients with short bowel syndrome.

Phase 3 randomized, double-blind, placebo-controlled trials in adult patients with SBS.

Phase 2 studies showed increased intestinal absorption of wet weight, energy, and macronutrients.

Short-term Phase 2 trials in SBS patients, though long-term safety requires ongoing monitoring.

04Preclinical evidence

Promoted significant intestinal growth and mucosal mass increase in animal models of short bowel syndrome.

Rodent and porcine models of intestinal resection.

Demonstrated a longer half-life compared to native GLP-2, allowing for less frequent dosing.

Pharmacokinetic studies in animal models.

05What is known vs. unknown

Reasonably established

Glepaglutide is a long-acting GLP-2 analog designed for subcutaneous administration.
It is primarily researched for short bowel syndrome (SBS) to reduce reliance on parenteral nutrition.
It works by promoting the growth of the intestinal lining and enhancing nutrient absorption.
Clinical trials have shown significant reductions in parenteral support volume in SBS patients.

Unknowns & limits

Long-term safety and potential risks of sustained intestinal mucosal growth (such as polyp formation) require further investigation.
The optimal dosing frequency (e.g., once or twice weekly) for balancing efficacy and patient convenience is still being refined.

06Safety & regulatory context

Regulatory statusGlepaglutide has been evaluated in Phase 3 clinical trials for short bowel syndrome and has received orphan drug designation in some regions. Common side effects observed in trials include injection site reactions, abdominal pain, nausea, and peripheral edema. Because it promotes tissue growth in the intestines, there is a theoretical risk of accelerating the growth of pre-existing intestinal polyps or tumors, necessitating careful screening. It is not yet fully FDA-approved for general use and remains under regulatory review.

07Compared with Teduglutide

Glepaglutide vs. Teduglutide

Key difference

Glepaglutide is designed with a longer half-life, potentially allowing for once- or twice-weekly dosing, whereas teduglutide typically requires daily injections.

When researchers discuss each

Researchers discuss teduglutide as the established, FDA-approved daily GLP-2 analog for SBS, while glepaglutide is discussed as a next-generation alternative offering less frequent dosing and potentially improved patient compliance.

08Glossary

Short Bowel Syndrome (SBS)

A condition where a large part of the small intestine is missing or damaged, leading to poor absorption of nutrients and fluids.

Parenteral Support

Intravenous feeding that provides patients with essential fluids, electrolytes, and nutrients when their digestive system cannot absorb enough.

GLP-2 (Glucagon-Like Peptide-2)

A naturally occurring hormone that promotes the growth and function of the intestinal lining.

09Knowledge check

Q1What is the primary mechanism of action for glepaglutide?

Q2What is the main clinical goal of glepaglutide treatment in short bowel syndrome?

Q3Which interpretation of the clinical evidence for glepaglutide is best supported by the dossier?

Q4What key difference do researchers emphasize between glepaglutide and teduglutide in the dossier?

Q5Which statement best reflects glepaglutide's safety and regulatory context as described in the dossier?

10Sources

More in Healing & Recovery

See all

BPC-157

Healing & Recovery

Early human

BPC-157 is a synthetic peptide sequence based on a protective compound naturally found in human gastric juice. Research suggests it has significant regenerative properties, promoting the healing of tendons, ligaments, muscles, and the gastrointestinal tract by accelerating angiogenesis and modulating growth factors.

250-500 mcg

TB-500 (Thymosin Beta-4)

Healing & Recovery

Early human

TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4. Research indicates it plays a crucial role in tissue repair, wound healing, and reducing inflammation by upregulating actin, a vital protein for cell structure and movement.

2.0 - 2.5 mg per injection

KPV

Healing & Recovery

Early human

KPV (Lys-Pro-Val) is a naturally occurring tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). Research highlights its potent anti-inflammatory and antimicrobial properties, making it a promising candidate for conditions like inflammatory bowel disease, skin disorders, and wound healing.

200-500 mcg/day

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.